obesity

Pfizer cans twice-daily oral obesity program after half of patients leave trial while once daily continues
Pfizer cans twice-daily oral obesity program after half of patients leave trial while once daily continues
Fierce Biotech
Pfizer
obesity
clinical trials
danuglipron
Flag link:
Altimmune Joins Weight-Loss Race with Phase II Win, Stock Jumps on News
Altimmune Joins Weight-Loss Race with Phase II Win, Stock Jumps on News
BioSpace
Altimmune
clinical trials
obesity
GLP-1 agonist
pemvidutide
Flag link:
Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters
Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters
BioSpace
Carmot Therapeutics
obesity
IPOs
Flag link:
Manufacturer Lonza says it will not fill obesity drug syringes
Manufacturer Lonza says it will not fill obesity drug syringes
Reuters
Lonza
drug manufacturing
obesity
Novo Nordisk
Eli Lilly
Flag link:
Novo Nordisk fights back at Lilly with Wegovy combo trial against Zepbound in obesity
Novo Nordisk fights back at Lilly with Wegovy combo trial against Zepbound in obesity
https://bit.ly/49zNkYL
Novo Nordisk
Eli Lilly
clinical trials
CagriSema
Wegovy
Zepbound
obesity
Flag link:
Novo Nordisk sets aside $6bn to boost production capacity
Novo Nordisk sets aside $6bn to boost production capacity
Pharmaphorum
Novo Nordisk
diabetes
obesity
drug manufacturing
Flag link:
AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug
AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drug
Fierce Biotech
AstraZeneca
obesity
sickle cell disease
Eccogene
earnings
Flag link:
An obesity drug biotech gets buy-in from Eli Lilly, venture firms
An obesity drug biotech gets buy-in from Eli Lilly, venture firms
BioPharma Dive
OrsoBio
Eli Lilly
funding
obesity
diabetes
Flag link:
'This field is in its infancy': Amgen noncommittal on oral obesity med until phase 1 data arrive
'This field is in its infancy': Amgen noncommittal on oral obesity med until phase 1 data arrive
Fierce Biotech
Amgen
obesity
AMG-786
Flag link:
Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro
Pfizer’s twice daily pill for obesity hopes to rival Wegovy and Mounjaro
Stat
Pfizer
danuglipron
obesity
Wegovy
Mounjaro
Novo Nordisk
Flag link:
GE HealthCare, Novo Nordisk partner to treat diabetes and obesity with ultrasound
GE HealthCare, Novo Nordisk partner to treat diabetes and obesity with ultrasound
Mass Device
Medtech
GE Healthcare
Novo Nordisk
PFUS
ultrasound
obesity
type 2 diabetes
Flag link:
Eli Lilly plans diabetes drug trial for kids as young as 6 years - Bloomberg
Eli Lilly plans diabetes drug trial for kids as young as 6 years - Bloomberg
Yahoo/Reuters
Eli Lilly
Mounjaro
obesity
pediatric
clinical trials
Flag link:
Boehringer moves obesity therapy into phase 3
Boehringer moves obesity therapy into phase 3
Pharmaphorum
Boehringer Ingelheim
Zealand Pharma
clinical trials
obesity
survodutide
Flag link:
Structure Therapeutics surges on promising early stage obesity drug data
Structure Therapeutics surges on promising early stage obesity drug data
Reuters
Structure Therapeutics
obesity
weight loss
clinical trials
GSBR-1290
Flag link:
Obesity Drug Market Set to Hit $100 Billion by 2035, BMO Says
Obesity Drug Market Set to Hit $100 Billion by 2035, BMO Says
Yahoo/Bloomberg
Novo Nordisk
Ozempic
Wegovy
obesity
weight loss
Flag link:
Altimmune completes dosing in MOMENTUM trial to treat obesity
Altimmune completes dosing in MOMENTUM trial to treat obesity
Clinical Trials Arena
Altimmune
clinical trials
pemvidutide
obesity
Flag link:
Novo, Lilly set to dominate $71B GLP-1 drug market by 2032: J.P. Morgan
Novo, Lilly set to dominate $71B GLP-1 drug market by 2032: J.P. Morgan
Fierce Pharma
Novo Nordisk
Eli Lilly
GLP-1 agonist
obesity
Flag link:
Novo Nordisk Is Already Working on Ozempic 2.0
Novo Nordisk Is Already Working on Ozempic 2.0
Motley Fool
Novo Nordisk
diabetes
obesity
weight loss
Ozempic
Wegovy
Flag link:
Novo Nordisk launches Wegovy for obese patients in UK
Novo Nordisk launches Wegovy for obese patients in UK
Pharmaceutical Business Review
Novo Nordisk
UK
Wegovy
obesity
Flag link:
Competing in These 3 Markets Could Send Eli Lilly Stock Soaring
Competing in These 3 Markets Could Send Eli Lilly Stock Soaring
Motley Fool
Eli Lilly
Alzheimer's disease
obesity
painkillers
Flag link:

Pages